Anglerfish, Gila Monsters, and the Origin of Weight Loss Drugs
Weight loss drug sales are estimated to hit $44 billion by 2030. Many of these treatments can thank previously obscure research on a carnivorous deep sea fish for their development. Rolfe Winkler is a reporter for the Wall Street Journal covering digital health. Ricky Mulvey caught up with Winkler to discuss: - The…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Motley Fool Hidden Gems Investing
See all episodes →
Similar episodes from other shows
More like Motley Fool Hidden Gems Investing →
Here's How the New Weight Loss Drugs Could Change Everything
The Big Business Behind Weight Loss Drugs
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
How Ozempic and Similar Weight Loss Drugs Really Work & The Story of Money
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.